Skip to content
InMed-logo-01
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
  • Pharmaceutical
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Cannabinoid Analogs
    • Cannabinoids in Development
  • Products
    • Cannabidivarin (CBDV)
    • Tetrahydrocannabivarin (THCV)
    • Cannabichromene (CBC)
    • Cannabicitran (CBT)
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
  • Pharmaceutical
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Cannabinoid Analogs
    • Cannabinoids in Development
  • Products
    • Cannabidivarin (CBDV)
    • Tetrahydrocannabivarin (THCV)
    • Cannabichromene (CBC)
    • Cannabicitran (CBT)
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
NASDAQ_Logo

Articles and Videos

Loading...
December 21, 2021
The Dales Report: InMed Pharmaceuticals – 2022 Looking Bright With Recent Acquisition Of BayMedica
The Dales Report Host Shadd Dales spoke with InMed CEO, Eric A. Adams, about plans for 2022. Excerpt from The Dales Report: Listed on the...
Source: The Dales Report
Read More
December 20, 2021
InMed Welcomes the BayMedica Team – Meet Research Scientist Dr. James Craig!
InMed Pharmaceuticals is pleased to welcome the BayMedica team following its acquisition in October 2021. Meet Dr. James Craig, one of our Research Scientists at...
Read More
December 15, 2021
InMed Welcomes the BayMedica Team – Welcome Dr. Jim Kealey, VP of Synthetic Biology
InMed Pharmaceuticals is pleased to welcome the BayMedica team following its acquisition in October 2021. Meet Dr. Jim Kealey, our VP of Synthetic Biology. Jim...
Source: Edison TV
Read More
December 8, 2021
InMed Welcomes the BayMedica Team! Welcome Dr. Charles Marlowe, VP of Chemistry
InMed Pharmaceuticals is pleased to welcome the BayMedica team following its acquisition in October 2021. Meet Dr. Charles Marlowe, our VP of Chemistry. Chuck talks...
Source: Edison TV
Read More
December 1, 2021
InMed Welcomes the BayMedica Team! Meet Philip Barr, VP of Discovery Research
InMed Pharmaceuticals is pleased to welcome to the BayMedica team following its acquisition in October 2021. Meet Philip Barr, our VP of Discovery Research. Phil...
Source: Edison TV
Read More
November 30, 2021
InMed’s Pharmaceutical Programs in Epidermolysis Bullosa and Glaucoma and Pharma Partnership Opportunities
In this excerpt from The Dales Report interview with host Shadd Dales, InMed's CEO Eric A. Adams talks about the Company's pharmaceutical programs in Epidermolysis...
Source: The Dales Report
Read More
« Previous 1 2 3 4 5 … 14 Next »

Novel Cannabinoid Analogs

Our patentable cannabinoid analogs can be slightly modified to target specific pharmacological properties.
Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.
SIGN UP
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Manufacturing

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis

Pharmaceutical

  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Novel Cannabinoid Analogs
  • Cannabinoids in Development

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

Products

  • Cannabidivarin (CBDV)
  • Tetrahydrocannabivarin (THCV)
  • Cannabichromene (CBC)
  • Cannabicitran (CBT)

About

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Events Calendar
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2022 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

Name*
Consent